Trials / Unknown
UnknownNCT04559607
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Zhongda Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.
Detailed description
This is a multicentric open-labal trial to evaluate the efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced hepatocellular carcinoma (HCC). The primary hypotheses is that TACE in combination with Camrelizumab and Apatinib is superior to TACE alone with respect to progression-free survival (PFS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Camrelizumab: 200mg, iv, Q3W |
| DEVICE | TACE | TACE if necessary |
| DRUG | Apatinib | Apatinib: 250m, po, QD |
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2024-08-31
- Completion
- 2026-01-31
- First posted
- 2020-09-23
- Last updated
- 2023-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04559607. Inclusion in this directory is not an endorsement.